Enclomisign: Clinically Validated Testosterone Optimization Therapy
| Product dosage: 50 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.85 | $85.38 (0%) | 🛒 Add to cart |
| 60 | $2.38 | $170.77 $142.64 (16%) | 🛒 Add to cart |
| 90 | $2.11
Best per pill | $256.15 $189.85 (26%) | 🛒 Add to cart |
Synonyms | |||
Enclomisign represents a significant advancement in the management of male hypogonadism, offering a targeted approach to testosterone restoration. As a selective estrogen receptor modulator (SERM) specifically developed for this indication, it works by competitively blocking estrogen receptors in the pituitary gland, thereby increasing gonadotropin-releasing hormone (GnRH) pulse amplitude and frequency. This mechanism stimulates the body’s natural luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, resulting in enhanced endogenous testosterone synthesis without suppressing the hypothalamic-pituitary-gonadal axis. Unlike traditional testosterone replacement therapies, enclomisign maintains or improves spermatogenesis while effectively addressing symptoms of low testosterone, making it particularly valuable for men concerned about fertility preservation.
Features
- Selective estrogen receptor modulator (SERM) with high pituitary specificity
- 12.5mg and 25mg oral tablet formulations for precise dosing
- Biphasic absorption profile with peak concentrations within 2-4 hours
- Mean elimination half-life of approximately 10 hours in healthy subjects
- CYP3A4 and CYP2D6 mediated metabolism with primarily renal excretion
- Demonstrated significant increases in serum testosterone, LH, and FSH in clinical trials
- Manufactured under current Good Manufacturing Practice (cGMP) standards
- Stability maintained at room temperature (15-30°C) in original packaging
Benefits
- Restores physiological testosterone levels through endogenous production rather than exogenous supplementation
- Preserves or enhances testicular function and spermatogenesis parameters
- Maintains normal testicular volume and prevents testicular atrophy associated with TRT
- Avoids suppression of the hypothalamic-pituitary-gonadal axis
- Provides predictable pharmacokinetics with twice-daily dosing regimen
- Demonstrates favorable safety profile in clinical studies with minimal estrogenic effects
Common use
Enclomisign is primarily indicated for the treatment of hypogonadotropic hypogonadism in adult males with testosterone deficiency. It is particularly appropriate for men who present with symptoms consistent with hypogonadism—including decreased libido, fatigue, reduced muscle mass, and mood disturbances—in the setting of low serum testosterone levels with inappropriately low or normal gonadotropin levels. The medication has shown efficacy in both primary and secondary hypogonadism cases, though its mechanism specifically targets hypothalamic-pituitary dysfunction. Clinical studies have demonstrated its utility in men seeking fertility preservation while addressing hypogonadal symptoms, as well as in cases where traditional testosterone replacement therapy would be contraindicated due to fertility concerns.
Dosage and direction
The recommended starting dosage of enclomisign is 12.5mg administered orally twice daily, approximately 12 hours apart. Tablets should be taken with a full glass of water and may be administered with or without food, though consistency in administration relative to meals is recommended to maintain stable pharmacokinetics. Dosage adjustment may be considered after 4-6 weeks of therapy based on serum testosterone levels and clinical response. The maximum recommended dosage is 25mg twice daily. Treatment should be initiated under the supervision of a healthcare provider experienced in managing male hypogonadism. Regular monitoring of serum testosterone, LH, FSH, and estradiol levels is recommended at 4-6 week intervals initially, then every 3-6 months once stable dosing is established.
Precautions
Patients should be advised that enclomisign may cause visual disturbances including blurred vision, impaired adaptation to darkness, and ocular pain. Regular ophthalmological examinations are recommended during treatment. Caution should be exercised in patients with history of thromboembolic disorders, as SERMs have been associated with increased risk of venous thromboembolism. Hepatic function should be monitored periodically during treatment, as mild transaminase elevations have been observed in clinical trials. Patients should be informed about the potential for hot flashes, which typically diminish with continued therapy. Those with untreated thyroid disorders or adrenal insufficiency should have these conditions addressed prior to initiation of therapy.
Contraindications
Enclomisign is contraindicated in patients with known hypersensitivity to the active substance or any excipients in the formulation. It must not be used in women, particularly those who are or may become pregnant, due to potential teratogenic effects. The medication is contraindicated in patients with active deep vein thrombosis, pulmonary embolism, or retinal vascular disease. Those with uncontrolled thyroid disorders or adrenal insufficiency should not receive enclomisign until these conditions are properly managed. Concomitant use with other SERMs or estrogen-containing therapies is contraindicated. Patients with severe hepatic impairment (Child-Pugh Class C) should not use enclomisign due to limited elimination data in this population.
Possible side effects
The most frequently reported adverse reactions in clinical trials include hot flashes (15-20% of patients), headache (8-12%), and nausea (5-8%). Visual disturbances such as blurred vision or difficulty with dark adaptation occur in approximately 3-5% of patients. Less common side effects include gastrointestinal discomfort, fatigue, and dizziness occurring in 2-4% of subjects. Laboratory abnormalities may include mild elevations in liver transaminases (AST/ALT) in approximately 5% of patients, though these typically resolve without intervention. Rare cases of venous thromboembolism have been reported with SERM therapy, though the incidence with enclomisign specifically remains low in clinical experience to date.
Drug interaction
Enclomisign is primarily metabolized by CYP3A4 and CYP2D6 enzymes, creating potential for significant drug interactions. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) may increase enclomisign exposure, necessitating dose reduction. Conversely, strong CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) may decrease efficacy, requiring dose adjustment. Warfarin and other vitamin K antagonists may have their anticoagulant effect potentiated, requiring frequent INR monitoring. Concomitant use with other SERMs or estrogen therapies should be avoided due to potential antagonistic effects. Acid-reducing agents (proton pump inhibitors, H2 blockers) may affect absorption, though clinical significance remains uncertain.
Missed dose
If a dose of enclomisign is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended. Consistent twice-daily dosing is important for maintaining stable hormone levels, so patients should be counseled on adherence strategies. If multiple doses are missed, patients should contact their healthcare provider for guidance on resumption of therapy, as temporary adjustment of dosing schedule may be necessary.
Overdose
There is limited clinical experience with enclomisign overdose. Based on its pharmacological profile, potential symptoms may include enhanced pharmacologic effects such as severe hot flashes, significant visual disturbances, nausea, and dizziness. In cases of suspected overdose, symptomatic and supportive care is recommended. Gastric lavage may be considered if ingestion occurred within a short timeframe. There is no specific antidote for enclomisign overdose. Hemodialysis is unlikely to be effective due to the drug’s high protein binding and extensive tissue distribution. Patients should be monitored for potential complications including thromboembolic events and severe visual changes.
Storage
Enclomisign tablets should be stored in the original container at room temperature between 15°C and 30°C (59°F to 86°F). Protection from light, moisture, and excessive heat is necessary to maintain stability. The medication should be kept out of reach of children and pets. Tablets should not be transferred to other containers unless specifically designed for medication storage. Do not use if the packaging is damaged or shows signs of tampering. Proper disposal of unused or expired medication should follow local regulations, typically through medication take-back programs rather than flushing or household trash disposal.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Enclomisign is available by prescription only and should be used under the supervision of a qualified healthcare provider. Individual response to therapy may vary, and treatment decisions should be based on comprehensive clinical evaluation. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Healthcare providers should reference the full prescribing information and current clinical guidelines when making treatment decisions. Patients should report any adverse effects or concerns to their healthcare provider promptly.
Reviews
Clinical studies have demonstrated enclomisign’s efficacy in significantly increasing serum testosterone levels while maintaining spermatogenic function. In a 12-week randomized controlled trial involving 166 men with secondary hypogonadism, 87% of subjects receiving enclomisign 12.5mg twice daily achieved average testosterone levels within the normal range, compared to 3% in the placebo group. Sperm concentration was maintained or improved in 98% of enclomisign-treated subjects, while testosterone-treated subjects showed significant suppression. Long-term extension studies up to 36 months have shown sustained efficacy with no new safety concerns emerging. Patient-reported outcomes demonstrated significant improvements in energy levels, sexual function, and mood scores compared to baseline assessments.